Bristol Myers Squibb reported Monday that its experimental therapy admilparant met the primary endpoint in a Phase 3 idiopathic pulmonary fibrosis trial, yet the stock finished the session down roughly four percent after an early pre-market rally evaporated. The contradiction, a statistically significant win at the lower dose and a miss at the higher one, left analysts describing the profile as confounding and investors punishing the shares of a rival developing a similar mechanism.
The dose-response puzzle
Over 52 weeks, patients receiving 60 milligrams of admilparant showed a meaningful slowing in the decline of forced vital capacity compared with placebo. The 120 milligram arm also demonstrated an effect on disease progression, but the difference from placebo failed to reach statistical significance. In respiratory drug development, regulators and clinicians typically expect higher doses to outperform lower ones; the absence of that gradient has become the focal point of debate.
Safety backdrop and analyst split
The readout arrives after Bristol Myers amended European safety monitoring protocols last month, a move that rekindled memories of an earlier LPA1 antagonist the company abandoned over liver toxicity. Monday’s release stated the drug “demonstrated a well-tolerated safety profile” and that treatment-related discontinuations were balanced across arms. RBC Capital Markets analyst Trung Huynh nonetheless labeled the high-dose result “confounding and requires further explanation.” Leerink Partners’ David Risinger wrote that approval remains plausible but the missing dose response “raises questions about the drug’s profile.” William Blair’s Matt Phipps countered that the lower-dose success “likely to open a blockbuster opportunity.”
Sector spillover
Contineum Therapeutics, which is advancing a different LPA1 antagonist in Phase 2, saw its shares drop about 30 percent in Monday morning trading as investors extrapolated the dose-response ambiguity across the class. Earlier LPA1 efforts have a checkered history: Amgen halted one candidate after a Phase 2 failure, and Bristol Myers itself shelved a prior molecule on hepatotoxicity grounds.
A second win in the same release
Separately, the company announced positive data from a late-stage study of RYZ-101, a radiopharmaceutical targeting certain neuroendocrine tumors. Bristol Myers acquired the asset through its $4.1 billion purchase of RayzeBio, adding a second potential catalyst to a day that the market ultimately treated as a net negative.